Search

Your search keyword '"Mansi, J.L."' showing total 35 results
Start Over Author "Mansi, J.L."
35 results on '"Mansi, J.L."'

1. 265P Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)

Author

Howell, S.J., primary, Krebs, M.G., additional, Lord, S., additional, Kenny, L., additional, Bahl, A., additional, Clack, G., additional, Ainscow, E., additional, Arkenau, H-T., additional, Mansi, J.L., additional, Palmieri, C., additional, Richards, P., additional, Jeselsohn, R., additional, Mitri, Z., additional, Gradishar, W.J., additional, Sardesai, S., additional, O'Shaughnessy, J., additional, Lehnert, M., additional, Ali, S., additional, McIntosh, S., additional, and Coombes, R.C., additional

Published
2021
Full Text
View/download PDF

2. 45P Long-term efficacy of neratinib in HER2-positive early-stage breast cancer: Overall survival and central nervous system outcomes from the phase III ExteNET trial

Author

Chan, A., primary, Moy, B., additional, Mansi, J.L., additional, Gnant, M.I., additional, Barrios, C.H., additional, Separovic, R., additional, Guerrero-Zotano, A., additional, Gore, I., additional, Smith, J., additional, Bryce, R.P., additional, Xu, F., additional, Wong, A., additional, Martin, M., additional, and Holmes, F.A., additional

Published
2021
Full Text
View/download PDF

3. 83P Impact of treatment duration of extended adjuvant therapy with neratinib in early stage HER2+ HR+ breast cancer after trastuzumab-based therapy on patient outcomes

Author

Martin Jimenez, M., primary, Gnant, M.I., additional, Ejlertsen, B., additional, Mansi, J.L., additional, Ruiz-Borrego, M., additional, Jakobsen, E.H., additional, Osborne, C.K., additional, Birhiray, R., additional, Zhang, B., additional, Wong, A., additional, Moy, B., additional, and Holmes, F.A., additional

Published
2020
Full Text
View/download PDF

8. A randomised trial of secondary prophylaxis using granulocyte colony-stimulating factor (‘SPROG’ trial) for maintaining dose intensity of standard adjuvant chemotherapy for breast cancer by the Anglo-Celtic Cooperative Group and NCRN

Author

Leonard, R.C.F., primary, Mansi, J.L., additional, Keerie, C., additional, Yellowlees, A., additional, Crawford, S., additional, Benstead, K., additional, Matthew, R., additional, Adamson, D., additional, Chan, S., additional, and Grieve, R., additional

Published
2015
Full Text
View/download PDF

10. An open-label study of lapatinib in women with HER-2-negative early breast cancer: the lapatinib pre-surgical study (LPS study)

Author

Coombes, R.C., primary, Tat, T., additional, Miller, M.L., additional, Reise, J.A., additional, Mansi, J.L., additional, Hadjiminas, D.J., additional, Shousha, S., additional, Elsheikh, S.E., additional, Lam, E. W-F., additional, Horimoto, Y., additional, El-Bahrawy, M., additional, Aboagye, E.O., additional, Contractor, K.B., additional, Shaw, J.A., additional, Walker, R.A., additional, Marconell, M.H., additional, Palmieri, C., additional, and Stebbing, J., additional

Published
2013
Full Text
View/download PDF

30. The bisphsphonate zoledronic acid impairs membrane localisation and induces cytochrome c release in breast cancer.

Author

Senaratne, S.G., Mansi, J.L., and Colston, K.W.

Subjects
*BREAST cancer, *DIPHOSPHONATES, *APOPTOSIS, *CYTOCHROME c
Abstract

Bisphosphonates are well established in the management of cancer-induced bone disease. Recent studies have indicated that these compounds have direct inhibitory effects on cultured human breast cancer cells. Nitrogen-containing bisphosphonates including zoledronic acid have been shown to induce apoptosis associated with PARP cleavage and DNA fragmentation. The aim of this study was to identify the signalling pathways involved. Forced expression of the anti-apoptotic protein bcl-2 attenuated bisphosphonate-induced loss of cell viability and induction of DNA fragmentation in MDA-MB-231 cells. Zoledronic acid-mediated apoptosis was associated with a time and dose-related release of mitochondrial cytochrome c into the cytosol in two cell lines. Rescue of cells by preincubation with a caspase-3 selective inhibitor and demonstration of procaspase-3 cleavage products by immunoblotting suggests that at least one of the caspases activated in response to zoledronic acid treatment is caspase-3. In both MDA-MB-231 and MCF-7 breast cancer cells, zotedronic acid impaired membrane Iocalisation of Ras indicating reduced prenylation of this proten. These observations demonstrate that zoledroric acidmediated apoptosis is associated with cytochrome c release and consequent caspase activation, This process may be initiated by inhibition of the enzymes in the mevalonate pathway leading to impaired prenylation of key intracellular proteins including Ras. [ABSTRACT FROM AUTHOR]

Published
2002
Full Text
View/download PDF

31. A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer.

Author

Evans, T.R.J., Colston, K.W., Lofts, F.J., Cunningham, D., Anthoney, D.A., Gogas, H., de Bono, J.S., Hamberg, K.J., Skov, T., and Mansi, J.L.

Subjects
PANCREATIC diseases, ANTINEOPLASTIC agents, HYPERCALCEMIA
Abstract

Inoperable cancer of the exocrine pancreas responds poorly to most conventional anti-cancer agents, and new agents are required to palliate this disease. Seocalcitol (EB1089), a vitamin D analogue, can inhibit growth, induce differentiation and induce apoptosis of cancer cell lines in vitro and can also inhibit growth of pancreatic cancer xenografts in vivo. Thirty-six patients with advanced pancreatic cancer received once daily oral treatment with seocalcitol with dose escalation every 2 weeks until hypercalcaemia occurred, following which patients continued with maintenance therapy. The most frequent toxicity was the anticipated dose-dependent hypercalcaemia, with most patients tolerating a dose of 10-15 microg per day in chronic administration. Fourteen patients completed at least 8 weeks of treatment and were evaluable for efficacy, whereas 22 patients were withdrawn prior to completing 8 weeks' treatment and in 20 of these patients withdrawal was due to clinical deterioration as a result of disease progression. No objective responses were observed, with five of 14 patients having stable disease in whom the duration of stable disease was 82-532 days (median=168 days). The time to treatment failure (n=36) ranged from 22 to 847 days, and with a median survival of approximately 100 days. Seocalcitol is well tolerated in pancreatic cancer but has no objective anti-tumour activity in advanced disease. Further studies are necessary to determine if this agent has any cytostatic activity in this malignancy in minimal disease states. [ABSTRACT FROM AUTHOR]

Published
2002
Full Text
View/download PDF

32. Myeloma and benign intracranial hypertension

Author

Wasan, H., Mansi, J.L., Benjamin, S., Powles, R., and Cunningham, D.

Subjects
Multiple myeloma -- Physiological aspects, Intracranial hypertension -- Physiological aspects, Health, Physiological aspects
Abstract

Benign intracranial hypertension in uncommon, with a prevalence of 0.9 per 100 000 and a noticeable female predominance (8:1). Several associations have been reported including with proliferative haematological disease such [...]

Published
1992

33. Detection of Tumor Cells in Bone Marrow of Patients with Prostatic Carcinoma by Immunocytochemical Techniques

Author

Mansi, J.L., Berger, U., Wilson, P., Shearer, R., and Coombes, R.C.

Abstract

We used a mixture of antisera to prostatic specific acid phosphatase, prostatic specific antigen, epithelial membrane antigen and cytokeratin to examine multiple marrow aspirates from patients with local (15) and metastatic prostatic carcinoma (15), and benign prostatic hypertrophy (10). We found moderate to large numbers of tumor cells in the bone marrow of 11 of 15 (73 per cent) patients with known metastatic disease and small numbers of abnormal cells in 2 of 15 (13 per cent) patients with apparently local disease. No tumor cells were found in patients with benign prostatic hypertrophy, and only 2 patients with metastatic disease had tumor cells in the bone marrow when conventional hematomorphological preparations were examined.

Published
1988
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results